Last updated: February 24, 2026
What is NDC 59385-0026?
NDC 59385-0026 is marketed as Viltolarsen, a splice-modifying antisense oligonucleotide developed by Daiichi Sankyo for the treatment of Duchenne muscular dystrophy (DMD) in patients with specific genetic mutations. Approved by the FDA in August 2020 under Orphan Drug status, Viltolarsen targets exon 53 skipping, addressing approximately 8-10% of the DMD patient population.
Market Overview
The global Duchenne muscular dystrophy market is expected to reach USD 2.33 billion by 2028, growing at a compound annual growth rate (CAGR) of 5.4% (Fortune Business Insights, 2022). The market comprises three primary segments: gene therapy, antisense oligonucleotides (ASOs), and corticosteroids. NDC 59385-0026 belongs to the ASO class, specifically exon-skipping agents.
Key Competitors and Market Share
| Product |
Drug Class |
Approval Date |
Estimated Worldwide Sales (2022) |
Market Share (2022) |
| Viltolarsen (NDC 59385-0026) |
Antisense oligonucleotide |
Aug 2020 |
USD 35 million |
4.4% |
| Eteplirsen (Exondys 51) |
Antisense oligonucleotide |
2016 |
USD 230 million |
28% |
| Casimersen (Amondys 45) |
Antisense oligonucleotide |
2020 |
USD 25 million |
3.1% |
| Drisapersen (Discontinued) |
Antisense oligonucleotide |
– |
N/A |
N/A |
Viltolarsen's market penetration is limited, owing to pricing, patent protections, and competitive efficacy. The primary challenge remains demonstrating long-term benefits over existing therapies.
Patient Population and Uptake
Approximately 15-20% of DMD cases involve mutations responsive to exon 53 skipping. The total DMD population worldwide exceeds 20,000, with US estimates at around 5,000 patients eligible for exon-skipping therapies. The adoption rate for NDC 59385-0026 remains low due to regulatory constraints, physician familiarity, and reimbursement barriers.
Price Projections
Current Pricing Landscape
The wholesale acquisition cost (WAC) of Viltolarsen is approximately USD 375,000 per year per patient, aligning with other exon-skipping agents:
| Drug |
WAC per Year |
Approval Year |
Market Penetration |
| Viltolarsen |
USD 375,000 |
2020 |
Limited |
| Eteplirsen |
USD 300,000 |
2016 |
Moderate |
| Casimersen |
USD 375,000 |
2020 |
Low |
Pricing reflects drug development costs, rarity, and regulatory exclusivity. The high yearly cost limits accessibility and reimbursement.
Future Price Trends
Projection assumptions:
- The price is expected to remain stable over the next 3-5 years in the absence of new comparators or patent expiration.
- Introduction of biosimilars or generics could lower prices by 20-30%, but this is unlikely within this period due to patent protections.
Price Forecast (2023–2028):
| Year |
Estimated WAC per Patient |
Rationale |
| 2023 |
USD 375,000 |
Stable pricing, high development costs maintained, limited competition. |
| 2024 |
USD 375,000 |
No significant patent expiry, reimbursement barriers persist. |
| 2025 |
USD 375,000 |
Market consolidation, no price pressure expected. |
| 2026 |
USD 375,000 |
Continued exclusivity, supply and demand dynamics unchanged. |
| 2027 |
USD 375,000 |
No new entrants or biosimilars, stable prices. |
| 2028 |
USD 375,000 |
Price remains stable; value-based pricing models may emerge but unlikely to impact WAC. |
Cost-Effectiveness and Reimbursement Factors
Reimbursements hinge on demonstrating clinical benefit. Payers demand long-term efficacy data, which remains under collection. The high upfront cost limits uptake unless patient outcomes show significant improvements. In some regions, value-based agreements could influence future pricing, possibly reducing net costs by 10-15%.
Key Market Dynamics
- Regulatory Environment: Orphan drug designation provides market exclusivity until at least 2030, protecting pricing.
- Manufacturing Costs: Antisense oligonucleotides involve high manufacturing expenses, justifying premium pricing.
- Reimbursement Landscape: Payers scrutinize cost-effectiveness; coverage is often conditional on demonstrable clinical benefit.
- Patient Access Programs: Limited, but expand as demand grows; discounts or patient assistance programs could lower effective costs.
Conclusion
NDC 59385-0026, Viltolarsen, competes within a niche market for exon 53 skipping in DMD. Its high price point is supported by rare disease economics, patent protections, and development costs. Market growth remains limited by pricing constraints and the slow adoption of new therapies, with price stability expected over the next five years unless regulatory changes or patent expirations occur.
Key Takeaways
- Viltolarsen’s annual cost remains around USD 375,000, with little change projected through 2028.
- Market share remains under 5% due to competition, reimbursement barriers, and limited patient access.
- The overall Duchenne market is growing, but NDC 59385-0026’s niche positioning constrains revenue potential.
- Pricing may see slight reductions if biosimilars or generics enter the market post-2030.
- Clinical data and long-term benefits are critical to expanding reimbursement and market penetration.
FAQs
1. What factors influence the price of Viltolarsen?
Manufacturing complexity, rarity of the disease, regulatory exclusivity, and the high cost of drug development influence pricing. Reimbursement negotiations and clinical benefit demonstrations also impact net costs.
2. Are biosimilars or generics expected for Viltolarsen?
Not within the next five years; patents protect exclusivity until at least 2030. Biosimilar development may begin after patent expiration.
3. How does Viltolarsen compare with Eteplirsen in efficacy?
Both demonstrate exon 53 skipping, but Eteplirsen has a broader evidence base and larger market share. Long-term comparative data are limited.
4. How do regulatory and reimbursement policies affect pricing?
Regulatory protections support high prices; reimbursement depends on clinical value assessments, which can constrain market penetration if benefits are not clearly established.
5. What are the growth prospects for NDC 59385-0026?
Limited unless new indications emerge, long-term efficacy data improve, or regulatory and pricing barriers are addressed.
Sources
[1] Fortune Business Insights. (2022). Duchenne Muscular Dystrophy Market Size, Share & Industry Analysis.
[2] U.S. Food and Drug Administration. (2020). FDA approves first drug to treat Duchenne muscular dystrophy.
[3] IQVIA. (2022). Oncology and Rare Disease Market Reports.
